New Human Study Published on Benegut's Digestive Health Benefits

Maypro Announces Clinical Study Supporting Digestive Health Benefits of Benegut®

 
PURCHASE, NY – JUNE 11, 2014 – Maypro Industries’ Proprietary Branded Ingredients (PBI) division is proud to announce the publication of a randomized, placebo-controlled, double-blind pilot study on a proprietary extract of Perilla frutescens extract (Benegut®) in healthy people with gastrointestinal discomfort.
 
The study, “Perilla Extract improves gastrointestinal (GI) discomfort in a randomized placebo controlled double blind human pilot study,” published in BMC Complementary and Alternative Medicine, and which was conducted by German researchers and led by Dr. Sybille Buchwald-Werner, investigated the effects of Benegut on GI discomfort in 50 healthy people aged 30 to 70 years who were given 150 mg of Benegut twice a day for 4 weeks.
 
Eighty percent of the participants who received Benegut reported substantial improvements in gastrointestinal discomfort. “The study results are very promising, taking into consideration the challenging set up of a nutritional study with healthy volunteers and the area of digestive health, which is known for high placebo effects,” noted Dr. Buchwald-Werner, Managing Director of Vital Solutions GmbH.
 
Benegut is standardized to its key active ingredient, Vicenin-2, as well as to rosmarinic acid and a special flavonoid fraction. It has been shown in human clinical and animal research to support gastrointestinal health by: (1) reducing occasional abdominal discomfort and feeling of fullness; (2) alleviating occasional gas and bloating; (3) improving daily regularity.*
 
Gastrointestinal discomfort is common, so any natural complement to the diets of consumers is very welcome. In fact, about 1 in 4 people in the U.S. have some activity limitation of daily function due to GI complaints.
 
“Considering the scope of these health concerns among Americans, and consequently the size of this market, I am very excited about the Benegut opportunity,” said Dan Lifton, President of Maypro’s PBI division. “I am grateful to our manufacturer partner for their commitment to high-quality clinical research, which positions us for success.”
 
Benegut® is a product of Vital Solutions, and is a high-quality, sustainable natural ingredient, one which is IP protected and approved for use in food supplements in Europe and the U.S.
 
Maypro Industries is an agent authorized to commercialize and market Benegut in the U.S.
 
The full study can be accessed here: http://www.biomedcentral.com/1472-6882/14/173
 
For more information on Benegut®, please click here: www.maypro.com/products/benegut.
 

About Maypro Industries

Maypro is headquartered in Purchase, N.Y., and has offices in Tokyo and Shanghai. Maypro Group is a global supplier of nutraceutical ingredients to the nutritional supplement, sports nutrition, pet & veterinary, cosmetic, functional food and fine chemical industries. Maypro is a minority-owned affiliate of Marubeni Corporation, one of Japan’s largest conglomerates and a Global Fortune 200 company with over US$40 billion in annual revenues and offices in 125 countries worldwide.
 

About Vital Solutions GmbH

Vital Solutions is a private limited corporation headquartered in Langenfeld, Germany. Vital Solutions works globally in the field of natural ingredients for use in food, functional food, dietary supplements and cosmetics.
 

IF YOU WOULD LIKE MORE INFORMATION ABOUT Benegut®, OR ABOUT ANY OF MAYPRO’S OTHER PROPRIETARY INGREDIENTS, PLEASE CONTACT DANIELLE.BERNARDO@MAYPRO.COM.

*These statements have not been evaluated by the Food & Drug Administration. This ingredient is not intended to diagnose, treat, cure or prevent any disease.